Since FOXM1 is a key regulator of cisplatin response in ovarian cancer, FOXM1 could be a new therapeutic target in ovarian cancer, and inhibition of FOXM1 would overcome cisplatin resistance. This evidence concerns the gene FOXM1 and ovarian cancer.